CD86 and inflammatory bowel disease: Furthermore, we found that genetically predicted HLA DR on CD14- CD16+ MC (OR: 0.84, 95% CI: 0.77–0.90, P=4.12 × 10−6), CD86+ plasmacytoid Dendritic Cell %Dendritic Cell (OR: 0.89, 95% CI: 0.84–0.94, P=5.01 × 10−5) and HVEM on T cell (OR: 0.92, 95% CI: 0.88–0.96, P=4.55 × 10−4) elevation reduced the risk of IBD (Table 2; Figure 2).